Imagen de Portada

The Backfill i3+3 Design for Dose-Finding Trials in Oncology

Fuente: arXiv

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu, Jiaxin, Yuan, Shijie, Bekele, B. Nebiyou, Ji, Yuan
Formato:	Preprint
Publicado:	2023
Materias:	Applications
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology
por: Liu, Jiaxin, et al.
Publicado: (2024)

Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
por: Yuan, Shijie, et al.
Publicado: (2023)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
por: Lee, Kyong Ju, et al.
Publicado: (2025)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
por: Chen, Yuxuan, et al.
Publicado: (2026)

SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
por: Yuan, Shijie, et al.
Publicado: (2025)

MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials
por: Lyu, Jiaying, et al.
Publicado: (2020)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
por: Hall, Andrew, et al.
Publicado: (2025)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
por: Li, Yuhan, et al.
Publicado: (2024)

Learning from Literature: Integrating LLMs and Bayesian Hierarchical Modeling for Oncology Trial Design
por: Gong, Guannan, et al.
Publicado: (2026)

Straightforward Phase I Dose-Finding Design for Healthy Volunteers Accounting for Surrogate Activity Biomarkers
por: Boulet, Sandrine, et al.
Publicado: (2024)

Regulatory Expectations for Bayesian Methods in Drug and Biologic Clinical Trials: A Practical Perspective on FDA's 2026 Draft Guidance
por: Ji, Yuan, et al.
Publicado: (2026)

Adaptive Phase 2/3 Design with Dose Optimization
por: Chen, Cong, et al.
Publicado: (2024)

Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies
por: Yuan, Shijie, et al.
Publicado: (2025)

Adjustment for Inconsistency in Adaptive Phase 2/3 Designs with Dose Optimization
por: Chen, Cong, et al.
Publicado: (2025)

Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs
por: Lu, Feinan, et al.
Publicado: (2024)

Joint TITE-CRM for Dual Agent Dose Finding Studies
por: Barnett, Helen, et al.
Publicado: (2025)

Robust Power and Sample Size Calculations in Quasi-likelihood Models: Methods and Practice
por: Yuan, Shijie, et al.
Publicado: (2026)

Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control
por: Maity, Arnab Kumar, et al.
Publicado: (2024)

Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
por: Sunami, Hisato, et al.
Publicado: (2024)

CUI-MET: Clinical Utility Index Dose Optimization Approach for Multiple-Dose, Multiple-Outcome Randomized Trial Designs
por: Zhang, Fanni, et al.
Publicado: (2025)

On the Calibration of Bayesian Success Criteria and Operating Characteristics for Clinical Trials
por: Yang, Peng, et al.
Publicado: (2026)

Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review
por: She, Jane, et al.
Publicado: (2026)

Modeling Time-Varying Effects of Mobile Health Interventions Using Longitudinal Functional Data from HeartSteps Micro-Randomized Trial
por: Yu, Jiaxin, et al.
Publicado: (2024)

Generalized Design of Basket Trials with P-value Combination Test
por: Zhou, Heng, et al.
Publicado: (2024)

Statistical Design and Rationale of the Biomarkers for Evaluating Spine Treatments (BEST) Trial
por: Sperger, John, et al.
Publicado: (2025)

Improving Maximum Tolerated Dose Selection in Model-Assisted Designs for Phase I Trials through Bayesian Dose-Response Model
por: Wakayama, Rentaro, et al.
Publicado: (2025)

A Bayesian Basket Trial Design Using Local Power Prior
por: Zhou, Haiming, et al.
Publicado: (2023)

Age-Dependent Heterogeneity in the Association Between Physical Activity and Mental Distress: A Causal Machine Learning Analysis of 3.2 Million U.S. Adults
por: Shan, Yuan
Publicado: (2026)

Bayesian Design and Analysis of Precision Trials with Partial Borrowing
por: Golchi, Shirin, et al.
Publicado: (2026)

Two-stage Adaptive Design Cluster Randomised Trials
por: Watson, Samuel I., et al.
Publicado: (2026)

Personalized Oncology: Feasibility of Evaluating Treatment Effects for Individual Patients
por: Jang, Lydia, et al.
Publicado: (2025)

Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
por: Amevor, Robert, et al.
Publicado: (2026)

Hybrid Non-informative and Informative Prior Model-assisted Designs for Mid-trial Dose Insertion
por: Yamada, Kana, et al.
Publicado: (2026)

Remote, bivariate expert elicitation to determine the prior probability distribution for sample size calculation in a Bayesian non-inferiority multicenter randomized controlled trial (Croup Dosing Trial)
por: Jiang, Arlene, et al.
Publicado: (2026)

On Assessing Overall Survival (OS) in Oncology Studies
por: Hsu, Jason C.
Publicado: (2025)

Second-order Asymptotic Analysis of Tail Probabilities of Randomly Weighted Sums: With Applications to a Bidimensional Discrete-time Risk Model
por: Geng, Bingzhen, et al.
Publicado: (2025)

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective
por: Chen, Jie, et al.
Publicado: (2024)

Dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials
por: Silva, Rebecca B., et al.
Publicado: (2025)

Sample size and power determination for assessing overall SNP effects in joint modeling of longitudinal and time-to-event data
por: Bian, Yuan, et al.
Publicado: (2026)

Same Prompt, Different Outcomes: Evaluating the Reproducibility of Data Analysis by LLMs
por: Cui, Jiaxin, et al.
Publicado: (2026)